Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Capital Leases (2016 - 2024)

Historic Capital Leases for Niagen Bioscience (NAGE) over the last 14 years, with Q3 2024 value amounting to $2000.0.

  • Niagen Bioscience's Capital Leases fell 8571.43% to $2000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $2000.0, marking a year-over-year decrease of 8571.43%. This contributed to the annual value of $12000.0 for FY2023, which is 4545.45% down from last year.
  • According to the latest figures from Q3 2024, Niagen Bioscience's Capital Leases is $2000.0, which was down 8571.43% from $6000.0 recorded in Q2 2024.
  • Over the past 5 years, Niagen Bioscience's Capital Leases peaked at $36000.0 during Q1 2020, and registered a low of $2000.0 during Q3 2024.
  • In the last 5 years, Niagen Bioscience's Capital Leases had a median value of $14000.0 in 2023 and averaged $16076.9.
  • As far as peak fluctuations go, Niagen Bioscience's Capital Leases soared by 1111.11% in 2020, and later plummeted by 8571.43% in 2024.
  • Niagen Bioscience's Capital Leases (Quarter) stood at $20000.0 in 2020, then crashed by 45.0% to $11000.0 in 2021, then soared by 100.0% to $22000.0 in 2022, then plummeted by 45.45% to $12000.0 in 2023, then tumbled by 83.33% to $2000.0 in 2024.
  • Its Capital Leases stands at $2000.0 for Q3 2024, versus $6000.0 for Q2 2024 and $9000.0 for Q1 2024.